Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older.
• People who are able and willing to give written consent to take part, or who have a legal representative able to give consent on their behalf if they cannot do so themselves.
• People who, in the trial doctor's judgment, are able to follow the study plan and attend required visits.
• People with a general health status rated 0, 1, or 2 on a standard scale used by doctors to measure how much a condition affects daily activities (confirm with trial site).
• People with a confirmed diagnosis that meets the trial's disease criteria, as shown on a pathology report.
• People whose most recent biopsy shows their tumour cells carry a marker called CD20.
• People whose disease did not respond adequately to a first standard treatment that included a type of chemotherapy drug (anthracycline) and an antibody targeting CD20.
• People for whom a doctor has determined that a specific type of CAR-T cell therapy (a specialised immune cell treatment targeting CD19) is appropriate and commercially available to them — for example, tisagenlecleucel, lisocabtagene maraleucel, or axicabtagene maraleucel.
• People with at least one measurable area of disease visible on a PET/CT scan, CT scan, or MRI, meeting specific size requirements (confirm with trial site).
• People whose recent blood test results meet the minimum levels required by the trial.
• People whose side effects from previous treatments have settled to a level that the trial doctor considers safe for participation.
• People who are willing and able to use appropriate contraception during the trial.

Who may not be able to join:

• People, or their legal representatives, who are unwilling or unable to provide consent.
• People who have previously had a solid organ transplant (such as a kidney, liver, or heart transplant).
• People with lymphoma that started in or is currently active in the brain or spinal cord at the time of screening.
• People with a history of autoimmune disease or other conditions that have caused permanent immune suppression or require ongoing immune-suppressing medication — though there are some exceptions, including: people with stable, treated underactive thyroid due to autoimmune causes; people with certain blood conditions related to lymphoma that are now in remission (subject to approval by the trial sponsor and principal investigator); and people with certain mild skin conditions (such as eczema, psoriasis, or vitiligo) that are well controlled, affect less than 10% of the body's skin surface, and are managed only with low-strength topical creams, with no severe flare-ups or stronger treatments needed in the past 3 months. People with conditions such as rheumatoid arthritis or similar autoimmune joint conditions are not eligible.
• People currently taking immune-suppressing medications (such as cyclophosphamide, azathioprine, methotrexate, thalidomide, or anti-TNF drugs), with certain exceptions for low-dose or short-term steroid use, inhaled steroids, or steroids used for specific medical management needs (confirm with trial site).
• People with another current or past cancer, apart from the condition being studied — though certain early-stage, treated, or low-risk cancers may be exceptions (confirm with trial site).
• People with known significant heart or cardiovascular disease.
• People with active or ongoing hepatitis B, hepatitis C, or HIV infection — though people with a past hepatitis B or C infection that has been successfully treated and shows no active virus in blood tests may not be excluded (confirm with trial site).
• People with an active bacterial, viral, fungal, or other serious infection at the time of enrolment, or who have needed intravenous antibiotics or a hospital stay for infection within 2 weeks before joining.
• People with significant lung disease that requires continuous oxygen use or high-dose steroid treatment.
• People with a seizure disorder that is not well controlled.
• People who have received a live vaccine within 4 weeks before signing the consent form.
• People who are pregnant or breastfeeding.
• People with any other serious medical condition or abnormal test result that, in the trial doctor's judgment, would make participation unsafe or affect the reliability of the trial results.

Important: Always verify eligibility with the trial site directly before applying.